Literature DB >> 11057957

Estimation of the under-reporting rate for the surveillance of Escherichia coli O157:H7 cases in Ontario, Canada.

P Michel1, J B Wilson, S W Martin, R C Clarke, S A McEwen, C L Gyles.   

Abstract

Two models estimating the proportion of Escherichia coli O157:H7 cases not reported in the Ontario notifiable diseases surveillance system are described. The first model is a linear series of adjustments in which the total number of reported cases is corrected by successive underreporting coefficients. The structure of the second model is based on a relative difference in the proportion of E. coli O157:H7 cases which are hospitalized between the surveillance database and the underlying population. Based on this analysis, the rate of under-reporting of symptomatic cases of E. coli O157:H7 infection in Ontario ranges from 78 to 88% corresponding to a ratio of 1 reported case for approximately 4-8 symptomatic cases missed by the surveillance system. This study highlights the need to increase awareness among public health workers of the potential biases that may exist in the interpretation of routine surveillance data.

Entities:  

Mesh:

Year:  2000        PMID: 11057957      PMCID: PMC2869567          DOI: 10.1017/s095026889900374x

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  8 in total

1.  Estimating the under-reporting rate for infectious gastrointestinal illness in Ontario.

Authors:  Shannon E Majowicz; Victoria L Edge; Aamir Fazil; W Bruce McNab; Kathryn A Doré; Paul N Sockett; James A Flint; Dean Middleton; Scott A McEwen; Jeffery B Wilson
Journal:  Can J Public Health       Date:  2005 May-Jun

2.  Mumps and the media: changes in the reporting of mumps in response to newspaper coverage.

Authors:  Babatunde Olowokure; Lilian Clark; Alex J Elliot; Douglas Harding; Ann Fleming
Journal:  J Epidemiol Community Health       Date:  2007-05       Impact factor: 3.710

3.  Epidemiological characteristics of reported sporadic and outbreak cases of E. coli O157 in people from Alberta, Canada (2000-2002): methodological challenges of comparing clustered to unclustered data.

Authors:  D L Pearl; M Louie; L Chui; K Doré; K M Grimsrud; S W Martin; P Michel; L W Svenson; S A McEwen
Journal:  Epidemiol Infect       Date:  2007-06-13       Impact factor: 2.451

4.  Broiler Campylobacter contamination and human campylobacteriosis in Iceland.

Authors:  Kenneth A Callicott; Hjördís Harğardóttir; Franklín Georgsson; Jarle Reiersen; Vala Friğriksdóttir; Eggert Gunnarsson; Pascal Michel; Jean-Robert Bisaillon; Karl G Kristinsson; Haraldur Briem; Kelli L Hiett; David S Needleman; Norman J Stern
Journal:  Appl Environ Microbiol       Date:  2008-09-12       Impact factor: 4.792

5.  Estimated Numbers of Community Cases of Illness Due to Salmonella, Campylobacter and Verotoxigenic Escherichia Coli: Pathogen-specific Community Rates.

Authors:  M Kate Thomas; Shannon E Majowicz; Paul N Sockett; Aamir Fazil; Frank Pollari; Kathryn Doré; James A Flint; Victoria L Edge
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-07       Impact factor: 2.471

6.  Cryptosporidium Attenuation across the Wastewater Treatment Train: Recycled Water Fit for Purpose.

Authors:  Brendon King; Stella Fanok; Renae Phillips; Melody Lau; Ben van den Akker; Paul Monis
Journal:  Appl Environ Microbiol       Date:  2017-02-15       Impact factor: 4.792

7.  Verotoxigenic Escherichia coli (VTEC): a major public health threat in Canada.

Authors:  David L Woodward; Clifford G Clark; Richard A Caldeira; Rafiq Ahmed; Frank G Rodgers
Journal:  Can J Infect Dis       Date:  2002-09

8.  Community incidence of pathogen-specific gastroenteritis: reconstructing the surveillance pyramid for seven pathogens in seven European Union member states.

Authors:  J A Haagsma; P L Geenen; S Ethelberg; A Fetsch; F Hansdotter; A Jansen; H Korsgaard; S J O'Brien; G Scavia; H Spitznagel; P Stefanoff; C C Tam; A H Havelaar
Journal:  Epidemiol Infect       Date:  2012-09-27       Impact factor: 4.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.